

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1 (Original). A method of treating a neoplasm in a mammal in need thereof, which comprises providing to said mammal an effective amount of a combination comprising CCI-779 and an aromatase inhibitor.

2 (Original). The method according to claim 1, wherein the aromatase inhibitor is selected from the group consisting of exemestane, formestane, atamestane, fadrozole, letrozole, vorozole, and anastrozole.

3 (Original). The method according to claim 2, wherein the aromatase inhibitor is letrozole.

4 (Original). The method according to claim 1, wherein the neoplasm is renal cancer.

5 (Original). The method according to claim 1, wherein the neoplasm is soft tissue sarcoma.

6 (Original). The method according to claim 1, wherein the neoplasm is breast cancer.

7 (Original). The method according to claim 1, wherein the neoplasm is a neuroendocrine tumor of the lung.

8 (Original). The method according to claim 1, wherein the neoplasm is cervical cancer.

9 (Original). The method according to claim 1, wherein the neoplasm is uterine cancer.

10 (Original). The method according to claim 1, wherein the neoplasm is a head and neck cancer.

11 (Original). The method according to claim 1, wherein the neoplasm is glioma.

12 (Original). The method according to claim 1, wherein the neoplasm is non-small cell lung cancer.

13 (Original). The method according to claim 1, wherein the neoplasm is prostate cancer.

14 (Original). The method according to claim 1, wherein the neoplasm is pancreatic cancer.

15 (Original). The method according to claim 1, wherein the neoplasm is lymphoma.

16 (Original). The method according to claim 1, wherein the neoplasm is melanoma.

17 (Original). The method according to claim 1, wherein the neoplasm is small cell lung cancer.

18 (Original). The method according to claim 1, wherein the neoplasm is ovarian cancer.

19 (Original). The method according to claim 1, wherein the neoplasm is colon cancer.

20 (Original). The method according to claim 1, wherein the neoplasm is esophageal cancer.

21 (Original). The method according to claim 1, wherein the neoplasm is gastric cancer.

22 (Original). The method according to claim 1, wherein the neoplasm is leukemia.

23 (Original). The method according to claim 1, wherein the neoplasm is colorectal cancer.

24 (Original). The method according to claim 1, wherein the neoplasm is unknown primary cancer.

25 (Original). A method of treating a neoplasm in a mammal in need thereof, which comprises providing to said mammal an effective amount of a combination comprising CCI-779 and an aromatase inhibitor, wherein either CCI-779, the aromatase inhibitor, or both are provided in subtherapeutically effective amounts.

26 (Original). The method according to claim 25 in which CCI-779 is provided in a subtherapeutically effective amount.

27 (Original). The method according to claim 25 in which the aromatase inhibitor is provided in a subtherapeutically effective amount.

28 (Original). The method according to claim 25 in which both CCI-779 and the aromatase inhibitor are provided in subtherapeutically effective amounts.

29 (Original). The method according to claim 25, wherein the aromatase inhibitor is letrozole.

30 (Original). An antineoplastic combination comprising an antineoplastic effective amount of a combination of CCI-779 and an aromatase inhibitor.

31 (Original). A method of treating a neoplasm in a mammal in need thereof, comprising providing to said mammal an effective amount of a combination comprising 42-O-(2-hydroxy)ethyl rapamycin and an aromatase inhibitor.

32 (Original). A method of treating an estrogen receptor positive carcinoma in a mammal in need thereof, comprising providing to said mammal an effective amount of a combination comprising CCI-779 and an aromatase inhibitor.

33 (Original). The method according to claim 32, wherein the aromatase inhibitor is selected from the group consisting of exemestane, formestane, atamestane, fadrozole, letrozole, vorozole, and anastrozole.

34 (Original). The method according to claim 33, wherein the aromatase inhibitor is letrozole.

35 (Original). The method according to claim 32, wherein the estrogen receptor positive carcinoma is of the breast cancer or ovarian cancer.

36 (Original). The method according to claim 35, wherein the aromatase inhibitor is letrozole.

37 (Original). The method according to claim 32, wherein the CCI-779 or the aromatase inhibitor, or both are provided in subtherapeutically effective amounts.

38 (Original). A method of treating an estrogen receptor positive carcinoma in a mammal in need thereof, comprising providing to said mammal an effective amount of a combination comprising 42-O-(2-hydroxy)ethyl rapamycin and an aromatase inhibitor.

39 (Original). A product containing (a) CCI-779 or 42-O-(2-hydroxy)ethyl rapamycin and (b) an aromatase inhibitor as a combined preparation for simultaneous, separate or sequential use in treating a neoplasm in a mammal in need thereof.

40 (Original). The product according to claim 39, wherein the aromatase inhibitor is selected from the group consisting of exemestane, formestane, atamestane, fadrozole, letrozole, vorozole, and anastrozole.

41 (Original). The product according to claim 40, wherein the aromatase inhibitor is letrozole.

42 (Original). A pharmaceutical pack containing a course of treatment of a neoplasm for one individual mammal, wherein the pack contains (a) units of CCI-779 or 42-O-(2-hydroxy)ethyl rapamycin in unit dosage form and (b) units of an aromatase inhibitor in unit dosage form.

43 (Original). A pharmaceutical pack according to claim 42, wherein the aromatase inhibitor is selected from the group consisting of exemestane, formestane, atamestane, fadrozole, letrozole, vorozole, and anastrozole.

44 (Original). A pharmaceutical pack according to claim 42, wherein the aromatase inhibitor is letrozole.

45 (Original). A pharmaceutical composition useful in treating a neoplasm in a mammal in need thereof, the composition comprising (a) CCI-779 or 42-O-(2-hydroxy)ethyl rapamycin and (b) an aromatase inhibitor in combination or association with a pharmaceutically acceptable carrier.

46 (Original). The pharmaceutical composition according to claim 45, wherein the aromatase inhibitor is selected from the group consisting of exemestane, formestane, atamestane, fadrozole, letrozole, vorozole, and anastrozole.

47 (Original). The pharmaceutical composition according to claim 46, wherein the aromatase inhibitor is letrozole.

48 (Original). An antineoplastic combination comprising an antineoplastic effective amount of a combination of 42-O-(2-hydroxy)ethyl rapamycin and an aromatase inhibitor.